Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QUARTZ: Dapagliflozin with Verinurad and Febuxostat in Hyperuricemia
NCT03316131Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2017
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dapagliflozin in Asymptomatic Hyperuricemia (AH), sponsored by AstraZeneca. Started Oct 2017; status: completed.
02
Drugs
dapagliflozin
03
Conditions
Asymptomatic Hyperuricemia (AH)
Beyond the preview
Go deeper on NCT03316131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03316131.